Special Offer. Now 25% off the original price of $1995.
Severe Acute Respiratory Syndrome (SARS), which was a new and unidentified disease when it first affected people, ripped through Asia and Toronto from late 2002 into the summer of 2003, before being contained for the season. Taiwan with just 346 reported cases performed 10,000 diagnostic tests. Three years after West Nile Virus (WNV) first appeared in the United States in 1999 with just 62 cases and 7 deaths, the U.S. Center for Disease Control reports thousands of cases and 150 to 250 deaths in 2002 and 2003. In 2003, WNV commercial and public testing is estimated to be a market worth over $100 million. Yellow Fever is the subject of a major vaccine and monitoring program. However, 2002 and 2003 were marked with two severe viral disease epidemic outbreaks.

The need to be able to easily, cheaply, and quickly diagnose these and other potential outbreak viral infections as public health problems in specific geographic regions, in addition to travel and bioterrorism concern, is driving the commercial development of several viral diagnostics.

This report focuses on diagnostic testing for 10 emerging viral infectious diseases:

• West Nile Virus (WNV)
• Severe Acute Respiratory Syndrome (SARS)
• Hantaviruses
• Ebola Virus
• Marburg Virus
• Crimean Congo
• Lassa Fever
• Yellow Fever
• Japanese Encephalitis
• Dengue

The main objectives of the study were to forecast testing volume and revenues in various regions and various populations, including human and other species. The report identifies the markets with the most potential for revenue, discusses competitors, and reports on available epidemiology.

Sensitivity, specificity, cost, speed, and volume of testing are all factors that regulate and drive the diagnostic technology development. For the diseases where there are large enough testing volumes, there are commercial diagnostic testing options and development, but otherwise home-brew ELISAs and PCR techniques are used. The technologies being used in the United States and worldwide and the technologies being developed are discussed, including

• ELISA
• Immunochromatographic Lateral Flow Strip Test
• Real Time Polymerase Chain Reaction (RT-PCR)
• Luminex Protein Bead
• NASBA
• AEGIS
• Transcription Mediated Amplification (TMA)

Information for this report has been collected from various industry, government, and academic sources. Interviews with numerous industry, government, and clinical participants form the core of the information found here. In addition, searches of the trade, business, and clinical literature were conducted to validate conclusions and fill in background, product, and company financial data where possible.

Related Reports:

The Clinical Laboratory Services Market (Growth Opportunities, Competitive Analysis and Competitor Profiles)
Feb 1, 2010 - KLI2565239 - $3,500.00

2009 Worldwide Diagnostics Market Research Bundle
Oct 1, 2009 - KLI2401913 - $5,995.00

Infectious Disease Diagnostic Markets
Aug 1, 2009 - KLI2391680 - $3,500.00

H1N1 (Swine Influenza) Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays and Molecular Assays)
May 1, 2009 - KLI2241990 - $800.00

The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 6th Edition [with 2009 economy preface]
Dec 1, 2008 - KLI1430266 - $3,995.00

The Clinical Laboratory Services Market (Growth Opportunities, Competitive Analysis and Competitor Profiles)
Nov 1, 2008 - KLI1646590 - $2,500.00

HIV: Markets for Diagnostics and Therapeutics
Oct 1, 2008 - KLI1646600 - $2,995.00

World HCV Testing, 2003 to 2007
Feb 21, 2006 - KLID1218013 - $800.00

U.S. Markets in Analytical Chip Technology: Gene, Protein, Tissue, Cell, and Microbiological Microarrays, 2nd Ed.
Jun 1, 2005 - KLI1087961 - $3,500.00

Diagnostics for Emerging Infectious Disease Threats Volume III: Bacterial Disease
Apr 1, 2004 - KLI895749 - $1,995.00